(RS)-1-tert-butyldimethylsilyloxy-3-phenoxy-2-propanol | 170375-42-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (RS)-1-tert-butyldimethylsilyloxy-3-phenoxy-2-propanol
• 英文别名: 1-(tert-butyldimethylsilyloxy)-3-phenoxypropan-2-ol；3-phenoxy-1-O-(tert-butyldimethylsilyl)propane-2-ol；1-[tert-butyl(dimethyl)silyl]oxy-3-phenoxypropan-2-ol
• CAS: 170375-42-5
• 化学式: C₁₅H₂₆O₃Si
• 分子量: 282.455
• InChiKey: HMDMQQPOPNXOBE-UHFFFAOYSA-N

物化性质

• 沸点：
  355.7±32.0 °C(predicted)
• 密度：
  0.989±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.45
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (RS)-1-tert-butyldimethylsilyloxy-3-phenoxy-2-propanol 在 四丙基高钌酸铵 、 葡萄糖 、 Yamadazyma farinosa IFO 10896 、 N-甲基吗啉氧化物 作用下， 以 phosphate buffer 、 二氯甲烷 为溶剂， 反应 54.0h， 生成 (S)-1-phenyl glycerol
  参考文献：
  名称：

  Microbial asymmetric reduction of α-hydroxyketones in the anti-Prelog selectivity

  摘要：

  Yamadazyma farinosa IFO 10896 was found to reduce alpha -hydroxyketones bearing a phenyl ring to give optically active diols with anti-Prelog selectivity. The distance between the carbonyl group and the phenyl ring was shown to have an interesting effect on the reactivity and selectivity of the enzyme system. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00448-7
• 作为产物：
  描述：

  苯基缩水甘油醚 在 吡啶 、 水 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (RS)-1-tert-butyldimethylsilyloxy-3-phenoxy-2-propanol
  参考文献：
  名称：

  [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE
  [FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON

  摘要：

  本文披露了抑制布鲁顿酪氨酸激酶（Btk）的化合物。还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症（包括淋巴瘤）和炎症性疾病或症状。

  公开号：

  WO2016004272A1

文献信息

• Imidazole compounds
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06359145B1

  公开（公告）日：2002-03-19

  Imidazole compounds having adenosine deaminase inhibitory activity represented by formula (I) wherein R1 is hydrogen, hydroxy, protected hydroxy, or aryl optionally substituted with suitable substituent(s); R2 is hydrogen or lower alkyl; R3 is hydroxy or protected hydroxy; R4 is cyano, (hydroxy)iminoamino(lower)alkyl, carboxy, protected carboxy, heterocyclic group optionally substituted with amino, or carbamoyl optionally substituted with suitable substituent(s); and —A— is —Q— or —O—Q—, wherein Q is single bond or lower alkylene, provided that when R2 is lower alkyl, then R1 is hydroxy, protected hydroxy, or aryl optionally substituted with suitable substituent(s), its prodrug, or their salt. The compounds are useful for treating and/or preventing diseases for which adenosine is effective.

  咪唑类化合物具有腺苷脱氨酶抑制活性，其化学式表示为（I），其中R1为氢、羟基、保护羟基或芳基，可选择地取代适当的取代基；R2为氢或较低的烷基；R3为羟基或保护羟基；R4为氰基、（羟基）亚氨基（较低）烷基、羧基、保护羧基、杂环基，可选择地取代氨基，或者羰酰基，可选择地取代适当的取代基；以及—A—为—Q—或—O—Q—，其中Q为单键或较低的烷基，条件是当R2为较低的烷基时，那么R1为羟基、保护羟基或芳基，可选择地取代适当的取代基，其前药或它们的盐。这些化合物可用于治疗和/或预防腺苷有效的疾病。
• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PHARMACYCLICS LLC

  公开号：WO2016004272A1

  公开（公告）日：2016-01-07

  Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了抑制布鲁顿酪氨酸激酶（Btk）的化合物。还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症（包括淋巴瘤）和炎症性疾病或症状。
• Using DMF as Both a Catalyst and Cosolvent for the Regioselective Silylation of Polyols and Diols
  作者：Jian Lv、Tao Luo、Dapeng Zou、Hai Dong

  DOI：10.1002/ejoc.201901195

  日期：2019.10.9

  discovered to be a good catalyst in the regioselective silylation of unprotected carbohydrates, although the silylation using DMF as a solvent has been a common method for more than 40 years. It has been demonstrated that a complex with a 1:1 ratio of the binding partners can be formed between TBSCl and DMF and has an association constant of 12/M, thus activating the silylation.

  尽管使用DMF作为溶剂的甲硅烷基化已超过40年，但已发现DMF是未保护碳水化合物在区域选择性甲硅烷基化中的良好催化剂。已经证明，可以在TBSC1和DMF之间形成具有1：1比例的结合配偶体的复合物，并且其缔合常数为12 / M，从而激活甲硅烷基化。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：CHEN Wei

  公开号：US20160002225A1

  公开（公告）日：2016-01-07

  Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了能够抑制布鲁顿酪氨酸激酶（Btk）的化合物。同时还描述了Btk的不可逆抑制剂。此外，还描述了可逆的Btk抑制剂。还披露了包括这些化合物的药物组合物。本文还披露了使用Btk抑制剂的方法，单独或与其他治疗药物联合使用，用于治疗自身免疫性疾病或情况，异体免疫性疾病或情况，癌症，包括淋巴瘤，以及炎症性疾病或情况。
• Microbial asymmetric reduction of α-hydroxyketones in the anti-Prelog selectivity
  作者：Toshikuni Tsujigami、Takeshi Sugai、Hiromichi Ohta

  DOI：10.1016/s0957-4166(01)00448-7

  日期：2001.10

  Yamadazyma farinosa IFO 10896 was found to reduce alpha -hydroxyketones bearing a phenyl ring to give optically active diols with anti-Prelog selectivity. The distance between the carbonyl group and the phenyl ring was shown to have an interesting effect on the reactivity and selectivity of the enzyme system. (C) 2001 Elsevier Science Ltd. All rights reserved.